DelMar Pharmaceuticals to Participate in Key Opinion Leader Luncheon on Glioblastoma Multiforme Featuring Dr. James Perry, MD March 2, 2017 • 8:30 AM EST
DelMar Pharmaceuticals Announces Dosing of the First Patient in Phase Two Clinical Trial of VAL-083 for MGMT-unmethylated Recurrent Glioblastoma Multiforme (GBM) February 13, 2017 • 8:40 AM EST
DelMar Pharmaceuticals Announces Second Quarter Fiscal Year 2017 Financial Results February 13, 2017 • 8:15 AM EST
DelMar Pharmaceuticals and MD Anderson Initiate New Phase Two Clinical Trial of VAL-083 for MGMT-unmethylated Recurrent Glioblastoma Multiforme (GBM) January 25, 2017 • 8:30 AM EST
DelMar Pharmaceuticals Receives Additional Non-Dilutive Funding from the Government of Canada to Support Expanded Research with Lead Product Candidate VAL-083 January 9, 2017 • 8:30 AM EST